Gradalis’ Vigil®: A Fully Personalized, Patient-Specific Cancer Immunotherapy For Ovarian Cancer
About The Event
Join us for the Gradalis KOL Event, featuring oncology experts Rodney Rocconi, MD, FACOG, Infirmary Cancer Care & O’Neal Comprehensive Cancer Center, UAB, and John Nemunaitis, MD, Chief Scientific Officer, Gradalis, who will discuss the current treatment landscape for patients with ovarian cancer and unmet medical needs. Gradalis is developing Vigil®, a novel, personalized cellular immunotherapy platform that is designed to decloak the full repertoire of a patient’s tumor neoantigens, reactivate the immune system, and summon key effector cells to deliver a durable clinical benefit.
Additionally, members of Gradalis’ leadership will discuss results from VITAL, a Phase 2b trial of Vigil® as maintenance therapy for ovarian cancer patients and the clinical development path forward.
A live Q&A session will follow the presentations.